AUR-107

N/A

Report date: 2024/02/27 11:49:14
NME

Base Information

Drug NameAUR-107
Drug Alias NameAUR107AUR-107
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActioncAMP-response element binding protein inhibitorsHistone acetyltransferase p300 inhibitors
TargetscAMP-response element binding proteinHistone acetyltransferase p300
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAurigene Discovery Technologies Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAurigene Discovery Technologies Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A